Imidazolium salts and derivatives have antitumor efficacy and toxic effects in different micro-organisms. In this study, an imidazolium bromide salt (NMI) was synthesized, and its antitumor potential was investigated by in vitro studies. Radiolabeling of synthesized NMI was carried out by iodogen method using I radionuclide. The yield of radiolabeling was determined as 98.5 ± 0.1%. After that, cytotoxicity and intracellular uptake studies were evaluated in various cell lines. The cytotoxicity of NMI was determined as 35, 20, 10, and 1 μm for HEK-293, PC-3, CaCo-2, and MCF-7 cells, respectively. In addition, the intracellular uptake of I-NMI was investigated in the cell lines, and the uptake was significantly found as 4 hr for MCF-7 and 6 hr for PC-3. In future studies, antitumor efficacy of I-NMI on tumor-bearing animal model might be studied in light of these results.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cbdd.12935DOI Listing

Publication Analysis

Top Keywords

antitumor efficacy
8
intracellular uptake
8
cell lines
8
synthesis investigation
4
investigation anticancer
4
anticancer potential
4
potential radiolabeled
4
radiolabeled naphthalene
4
naphthalene monoimide
4
monoimide bearing
4

Similar Publications

Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and degraders/downregulators (SERMs and SERDs) show clinical efficacy, but responses are often non-durable.

View Article and Find Full Text PDF

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.

View Article and Find Full Text PDF

The clinical potential of current chimeric antigen receptor-engineered T (CAR-T) cell therapy is hampered by its autologous nature that poses considerable challenges in manufacturing, costs and patient selection. This spurs demand for off-the-shelf therapies. Here we introduce an ex vivo feeder-free culture method to differentiate gene-engineered hematopoietic stem and progenitor (HSP) cells into allogeneic invariant natural killer T (NKT) cells and their CAR-armed derivatives (CAR-NKT cells).

View Article and Find Full Text PDF

Purpose: Immune checkpoint blockades (ICBs) are promising, however they do not fit all types of tumor, such as those lack of tumor antigens. Induction of potent anti-tumor T cell immunity is critical for cancer therapy. In this study, we investigated the efficacy of immunotherapy via the immunogenic cell death (ICD) dying tumor cells in mouse models of lung metastasis and tumorigenesis.

View Article and Find Full Text PDF

Silver N-heterocyclic carbene (NHC) complexes are known to form biscarbene species from monocarbene analogs in protic polar solvents. However, the effect of the respective species of silver NHC complexes on their biological activity against bacteria or cancer cells has not been systematically explored, either in vitro or in vivo. The direct and simple conversion of monocarbene silver N-heterocyclic carbene (NHC) halide complexes (NHC)AgX, (X= Cl, Br) 1a/b - 5a/b to their biscarbene analogues (NHC)2AgX 1c/d - 5c/d is reported.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!